| Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial N Al Kaabi, Y Zhang, S Xia, Y Yang, MM Al Qahtani, N Abdulrazzaq, ... Jama 326 (1), 35-45, 2021 | 822 | 2021 |
| Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial NA Kaabi, YK Yang, LF Du, K Xu, S Shao, Y Liang, Y Kang, JG Su, ... Nature Communications 13 (1), 3654, 2022 | 31 | 2022 |
| Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates N Al Kaabi, A Oulhaj, S Ganesan, FI Al Hosani, O Najim, H Ibrahim, ... Nature Communications 13 (1), 3215, 2022 | 26 | 2022 |
| Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial NA Kaabi, YK Yang, J Zhang, K Xu, Y Liang, Y Kang, JG Su, T Yang, ... Signal Transduction and Targeted Therapy 7 (1), 172, 2022 | 24 | 2022 |
| The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates N Al Kaabi, A Oulhaj, FI Al Hosani, S Al Mazrouei, O Najim, SE Hussein, ... Scientific reports 12 (1), 490, 2022 | 12 | 2022 |
| Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine: an interim analysis S Toback, AM Marchese, B Warren, S Ayman, S Zarkovic, I ElTantawy, ... medRxiv, 2023.03. 24.23287658, 2023 | 3 | 2023 |
| Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded … N AlKaabi, YK Yang, J Zhang, K Xu, Y Liang, Y Kang, JG Su, T Yang, ... medRxiv, 2021.12. 29.21268499, 2022 | 3 | 2022 |
| Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial NA Kaabi, YK Yang, Y Liang, K Xu, XF Zhang, Y Kang, YQ Jin, JW Hou, ... Signal Transduction and Targeted Therapy 8 (1), 20, 2023 | 1 | 2023 |
| Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants NA Kaabi, YK Yang, Y Liang, K Xu, XF Zhang, Y Kang, YQ Jin, JW Hou, ... medRxiv, 2022.09. 05.22279589, 2022 | 1 | 2022 |
| Assessing and addressing barriers towards MDI use in acute asthma exacerbations at a tertiary pediatric ED in the United Arab Emirates NF Sakrani, SE Hussein, M Borg, S Konstantinopoulou International Journal of Pediatrics and Adolescent Medicine 9 (1), 41-45, 2022 | | 2022 |
| Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial (preprint) N Al Kaabi, YK Yang, LF Du, K Xu, S Shao, Y Liang, Y Kang, JG Su, ... | | 2022 |
